Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 3/20 | 0.61 |
| ▸ | NAAA | Q02083 | 1/20 | 0.51 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.51 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.51 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9000841 | 1.00 | PRCP (0.61) | PRCPNAAAGNAI3GNAO1GNAI1 | |
| SCHEMBL11742492 | 1.00 | PRCP (0.61) | PRCPNAAAGNAI3GNAO1GNAI1 | |
| SCHEMBL11840759 | 1.00 | PRCP (0.61) | PRCPNAAAGNAI3GNAO1GNAI1 | |
| SCHEMBL7510214 | 1.00 | PRCP (0.61) | PRCPNAAAGNAI3GNAO1GNAI1 | |
| SCHEMBL11853350 | 1.00 | PRCP (0.61) | PRCPNAAAGNAI3GNAO1GNAI1 | |
| SCHEMBL11746495 | 0.98 | PRCP (0.59) | PRCPNAAAGNAI3GNAO1GNAI1 | |
| SCHEMBL26721345 | 0.95 | PRCP (0.56) | PRCPNAAAGNAI3GNAO1GNAI1 | |
| SCHEMBL17484764 | 0.95 | PRCP (0.56) | PRCPNAAAGNAI3GNAO1GNAI1 | |
| SCHEMBL26721427 | 0.95 | PRCP (0.56) | PRCPNAAAGNAI3GNAO1GNAI1 | |
| SCHEMBL26721243 | 0.95 | PRCP (0.56) | PRCPNAAAGNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020072601-A1 | Method for forming amino acid derivatives from tricyclic diketopiperazines | UNIVERSITY OF SOUTHERN MISSISSIPPI | 2002-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072601-A1 | Method for forming amino acid derivatives from tricyclic diketopiperazines | AADAT, GLUL, ASNS | PRCP 1912/4885NAAA 80/4885GNAI3 1970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.